The Diabetes Research Connection is proud to partner with Beyond Type 1 to accelerate the most promising efforts for a cure for Type 1 diabetes. This is one of many projects we’re excited to partner on. Gifts start at $1 and 100% of your funds designated for research go directly to the lab. To date, $8,002 of a necessary $50,000 has been raised to move forward with this idea.
Have you heard about the handful of Diabetes Research Institute (DRI) patients that went without insulin for 10 years after cell replacement therapy? Their results showed that we can restore insulin production in those with Type 1 diabetes and that a biological cure is possible.
This treatment is not available (yet) to the millions with diabetes. While it was effective for some and improved their quality of life, the issue of cell survival and need for immunosuppressants post-transplant remains. Can a new location for the islet cell BioHub or “mini-organ” remedy these issues? The liver, the site used previously, has an adequate blood supply and is an easy-to-access location; however, it is the body’s filter for toxins, so the cells are exposed to waste, which decreases their longevity.
Dr. David Baidal at DRI believes that there may be a better location for cell replacement therapy: the omentum, a layer of fatty tissue that covers the organs in the lower abdomen. Like the liver, it’s close to the surface and is also highly vascularized. The big difference is it isn’t surrounded by waste and has an even larger surface area for scientists to work with.
DRI says there have been “encouraging preliminary results in animal models have demonstrated that islets in the omentum can engraft (become lodged in the tissue, get their own vessels and start producing insulin) and improve blood glucose control.”
With approval from the FDA, a new clinical trial is now underway in humans.
The DRI BioHub is a bioengineered mini-organ designed to mimic the pancreas. “The islets are transplanted within a fully-resorbable (biodegradable) biologic scaffold consisting of the patient’s plasma (the liquid part of the blood that does not contain cells) and human thrombin, a clotting enzyme commonly used in surgical procedures,” explains DRC.
“The biologic scaffold will serve as a platform that adheres to the omentum and holds the islets in place. The patients in this clinical trial will require the same immunosuppressive (anti-rejection) drug regimen as used in islet transplants within the liver. However, our goal at the DRI is to eliminate the need for these drugs. The development of the DRI BioHub, together with several other areas of research strategies underway at the Institute, are aimed at overcoming challenges of the immune system.”
You can fund this project directly! Researchers have raised $8,000 of a necessary $50,000 to move forward with this idea. Let’s make it happen.